Prodigy Investment
VC Fund
Seoul, South Korea
Prodigy Investment is a venture capital firm.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Prodigy Investment invests in
Stages Prodigy Investment invests in
Countries Prodigy Investment invests in
Investment Focus
Industry
- Biotechnology 4 (33%)
- Information Technology 4 (33%)
- Health Care 3 (25%)
- SaaS 2 (17%)
- Medical 2 (17%)
Stage
- Series B 4 (33%)
- Series A 3 (25%)
- Seed 2 (17%)
- Series C 2 (17%)
- Venture - Series Unknown 1 (8%)
Country
- South Korea 9 (75%)
- Indonesia 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Comfo Labs
|
Comfo Labs is an innovative human-centered ergonomics and digital technology company that leverages large-scale 3D human data and AI simulation to validate product usability, fit, and safety from the earliest stages of design. | Seed / Aug 05, 2026 | |
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
Micro-one
|
Micro-One is an air functionality expert company that manufactures incinerators, ecological infrastructure, and advanced dust filters. | $4.6M / Venture - Series Unknown / Jan 13, 2025 | |
Cellemedy
|
Cellemedy is a biotechnology company committed to developing next-generation therapeutic proteins aimed at replacing conventional antibody treatments. Their proprietary platform offers enhanced antigen-binding capabilities and broader applicability compared to traditional antibodies. Its mission is to advance human health by creating innovativebiopharmaceuticals that improve treatment outcomes across various medical conditions. | $7.4M / Series A / Oct 04, 2023 | |
|
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $15.6M / Series B / Jul 24, 2023 | |
Yulift
|
Yulift is an edtech company that develops AI and coding education platforms for beginners and aspiring developers. The company operates AI Coding Valley, a mobile-based learning platform that provides programming and artificial intelligence education content for beginners and students. | $2M / Seed / Feb 06, 2023 | |
Plugo
|
Plugo is an all-in-one e-commerce platform that empowers anyone who wants to start an online business. Plugo lets users personalize their online stores with custom website templates, payment and courier integrations, omnichannel, SEO, and marketing tools. Plugo is entirely cloud-based and hosted, allowing users to access and manage their businessfrom anywhere, at any time, while on the go. | $9M / Series A / Dec 14, 2022 | |
MetaFines
|
MetaFines is a biopharma firm that creates anticancer medications with the goal of preventing the spread of cancer. By extending and reconfiguring the indications of off-label medications for terminal tumors, the company creates minimal anticancer pharmaceuticals. It also provides subcutaneous injections and therapies, allowing patients to fightcancer and enhance their standard of living with cancer metabolism.The company develops ow-toxic medicines for metabolic cancer. This low-toxic metabolic anti-cancer agent is distinguished by being created so that metabolic anti-cancer agents that limit cell growth but operate via various pathways can work in concert with one another. | $15.7M / Series B / Apr 28, 2022 | |
CodeBrick
|
Codebrick is a technical co-founder for local SEA entrepreneurs. Codebrick is a technical co-founder for local SEA entrepreneurs. Codebrick operates as an equity partner -this aligns the interests of the technical co-founder with those of the entrepreneur. | $12M / Series B / Jun 28, 2021 | |
AbTis
|
AbTis is a biotechnology company that provides antibody-drug conjugation technology and solubilization. | $13.5M / Series B / Feb 02, 2021 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Prodigy Investment invest in?
Prodigy Investment invests primarily in Biotechnology, Information Technology and Health Care startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Prodigy Investment last invest?
The most recent investment recorded for Prodigy Investment closed in Aug 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
